Royalty Pharma to pay up to $950 million for royalties from Amgen’s lung cancer drug
(Reuters) -Royalty Pharma has agreed to buy a royalty interest in Amgen’s drug for small cell lung cancer from BeOne Medicines for up to $950 million, it said on Monday. Shares of biotech investor Royalty Pharma were up 1.5% in morning trade. The deal gives Royalty Pharma access to roughly 7% of global net sales …
Royalty Pharma to pay up to $950 million for royalties from Amgen’s lung cancer drug Read More »










